Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Here's Why Insmed Incorporated Is Skyrocketing
Here's Why Insmed Incorporated Is Skyrocketing
Investors in Insmed (NASDAQ: INSM) are having an incredible start to the short trading week. Shares of the rare disease focused biotech are up 110% as of 11:15 a.m. EDT, after the company....
The 2 Major Catalysts Behind Myriad Genetics, Inc.'s 26% Gain in August
The 2 Major Catalysts Behind Myriad Genetics, Inc.'s 26% Gain in August
Shares of Myriad Genetics (NASDAQ: MYGN), a leading developer of molecular diagnostic tests, surged by 26% during the month of August, according to data from S&P Global Market Intelligence.....
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
Shares of Incyte (NASDAQ: INCY), a large-cap biotech company primarily focused on developing therapies to treat cancer and inflammatory diseases, tacked on more than $4 per share, or $850 million....
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
Shares of Incyte (NASDAQ: INCY), a large-cap biotech company primarily focused on developing therapies to treat cancer and inflammatory diseases, tacked on more than $4 per share, or $850 million....
Why This Marijuana Stock Crashed 18.5% in August
Why This Marijuana Stock Crashed 18.5% in August
Arizona's attorney general is suing Insys Therapeutics (NASDAQ: INSY) over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company's shares to tumble 18.5% in August,....
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....

	 
BASTIDE : Cessation du contrat de liquidité contracté avec Gilbert Dupont - Mise en oeuvre d'un contrat de liquidité avec Natixis (ERRATUM)
BASTIDE : Cessation du contrat de liquidité contracté avec Gilbert Dupont - Mise en oeuvre d'un contrat de liquidité avec Natixis (ERRATUM)
Le 4 septembre 2017   A effet du 4 septembre 2017, il a été mis fin au contrat de liquidité confié par la société Bastide Groupe à Gilbert Dupont. A cette date, les moyens suivants figuraient....

	 
BASTIDE : Nombre d'actions et de droits de vote au 31 aout 2017
BASTIDE : Nombre d'actions et de droits de vote au 31 aout 2017
BASTIDE LE CONFORT MEDICAL Société Anonyme au capital de 3.303.261 euros Siège social : 12 avenue de la Dame, Zone Euro 2000 30132 Caissargues RCS de NIMES N° B 305 635 039 DROITS DE....

	 
BASTIDE : Cessation du contrat de liquidité contracté avec Gilbert Dupont - Mise en oeuvre d'un contrat de liquidité avec Natixis
BASTIDE : Cessation du contrat de liquidité contracté avec Gilbert Dupont - Mise en oeuvre d'un contrat de liquidité avec Natixis
Le 4 septembre 2017   A effet du 4 septembre 2017, il a été mis fin au contrat de liquidité confié par la société Bastide Groupe à Gilbert Dupont. A cette date, les moyens suivants figuraient....
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
I bought my shares of Johnson & Johnson (NYSE: JNJ) and Gilead Sciences, Inc. (NASDAQ: GILD) long ago, when they were trading far lower than they are today. If I had to choose one to keep and....
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
I bought my shares of Johnson & Johnson (NYSE: JNJ) and Gilead Sciences, Inc. (NASDAQ: GILD) long ago, when they were trading far lower than they are today. If I had to choose one to keep and....
Here's the Best Dividend Stock in Big Pharma
Here's the Best Dividend Stock in Big Pharma
Dividends make a huge impact on your overall investing returns. They can also provide solid income during your retirement years. Historically, big pharma stocks have been a great place for....
Here's the Best Dividend Stock in Big Pharma
Here's the Best Dividend Stock in Big Pharma
Dividends make a huge impact on your overall investing returns. They can also provide solid income during your retirement years. Historically, big pharma stocks have been a great place for....
Why Gilead Sciences Shares Soared 10.6% in August
Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market....
Why Gilead Sciences Shares Soared 10.6% in August
Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market....
Why Gilead Sciences Shares Soared 10.6% in August
Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market....
3 Charts That Show Why Aurinia Pharmaceuticals Stock Could Go Higher
3 Charts That Show Why Aurinia Pharmaceuticals Stock Could Go Higher
Aurinia Pharmaceuticals (NASDAQ: AUPH) stock is without question one of the best-performing biotech stocks so far in 2017. Shares of the red-hot biotech have tripled in price year to date. Aurinia....
94% of Americans Support Legalizing Medical Marijuana, but Not Congress
94% of Americans Support Legalizing Medical Marijuana, but Not Congress
When it comes to the fastest, most consistently growing industries in the U.S. right now, legal marijuana is near the top of the list. Investment firm Cowen & Co. has predicted that U.S. legal....
3 Biotech Stocks That Skyrocketed This Week
3 Biotech Stocks That Skyrocketed This Week
If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by....
3 Biotech Stocks That Skyrocketed This Week
3 Biotech Stocks That Skyrocketed This Week
If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by....
3 Biotech Stocks That Skyrocketed This Week
3 Biotech Stocks That Skyrocketed This Week
If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by....
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
In a previous article, I laid out the bear case against Intuitive Surgical (NASDAQ: ISRG). Today, I'm looking at some ways the robotic surgery leader's stock could trend higher in the years....
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
In a previous article, I laid out the bear case against Intuitive Surgical (NASDAQ: ISRG). Today, I'm looking at some ways the robotic surgery leader's stock could trend higher in the years....